Evidence map›Paper›PMID 41660516›Full record

ArticleFrontiers in pharmacology2026

Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study.

Xueyuan Guo, Juan Du, Yuehui Yin, Heng Qi, Zhisheng Jia, Xiaojun Ji, Yuqing Zhang, Xue Liang, Bing Deng, Jieyun Liu and 15 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04747496 (Real-world Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation in China), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04747496 completednot on this map

Real-world Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation in China

TypeobservationalSponsorDaiichi SankyoRan2021 to 2024Enrolled5,000ConditionsNon-valvular Atrial FibrillationArmsEdoxaban
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Xueyuan GuoBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Juan DuDaiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China.
Yuehui YinThe Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Heng QiThe First Hospital of Changsha, Changsha, China.
Zhisheng JiaThe Fifth People's Hospital of Jinan, Jinan, China.
Xiaojun JiWenzhou Central Hospital, Wenzhou, China.
Yuqing ZhangNanjing Jiangning Hospital, Nanjing, China.
Xue LiangThe Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bing DengLonghua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jieyun LiuKaifeng Central Hospital, Kaifeng, China.
Juan MaThe First Hospital of Kunming, Kunming, China.
Cangsang SongThe First Hospital of Kunming, Kunming, China.
Huifang FengTaiyuan Central Hospital of Shanxi Medical University, Taiyuan, China.
Suxin LuoThe First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jingfeng WangSun Yat-sen Memorial hospital, Sun Yat-sen University, Guangzhou, China.
Yongqi XiaoThe Third People's Hospital of Nanning, Nanning, China.
Lun LiWuhan Puai Hospital, Wuhan, China.
Junyou CuiJiangyin People's Hospital, Wuxi, China.
Zheng HuangThe First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiang ChengUnion Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Yuan YiDaiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China.
Mengqi LiuDaiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China.
Cathy ChenDaiichi Sankyo Inc., Basking Ridge, NJ, United States.
Martin UnverdorbenDaiichi Sankyo Inc., Basking Ridge, NJ, United States.
Changsheng MaBeijing Anzhen Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF). However, studies on the effectiveness and safety of edoxaban for Chinese patients with AF, are limited. Methods: We report the 1-year interim follow-up data on edoxaban use in Chinese patients with AF from the ETNA-AF-China (NCT04747496), a multicentre, prospective, observational study conducted in 89 centres across the Chinese Mainland, enrolling 5,001 patients with a total of 2-year follow-up. No adjustment for multiple testing was made; therefore, all Results: Overall, 4,877 patients (60 mg edoxaban: 54.3%; 30 mg edoxaban: 45.7%) completed 1-year follow-up (mean age ± standard deviation: 70.3 ± 9.5 years; mean CHA Conclusion: In a large Chinese AF population, edoxaban showed low incidences of stroke and bleeding, notably major bleeding, ICH, major gastrointestinal bleeding, and CV mortalities, with the majority of patients still on edoxaban at the end of 1-year follow-up.

Indexed as

atrial fibrillationChineseedoxabannon–vitamin K antagonist oral anticoagulantsreal-world

Identifiers

PMID41660516
PMCPMC12872560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.